{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-014759","form_type":"8-K","ticker":"PFE","cik":"0000078003","company_name":"PFIZER INC","filed_at":"2023-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.215422+00:00","generated_at":"2026-06-16T04:13:52.145185+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Pfizer Q1 revenue falls 29% to $18.3B; adjusted EPS $1.23; reaffirms FY2023 guidance","bullets":["First-quarter 2023 revenues $18.3B (down 29% YoY); reported diluted EPS $0.97, adjusted diluted EPS $1.23 (down 24% YoY).","Comirnaty revenues dropped 75% operationally; Paxlovid revenues increased by $2.8B; ex-COVID products grew 5% operationally.","FY2023 guidance reaffirmed: revenue $67-71B, adjusted EPS $3.25-3.45; midpoint implies ~31% operational revenue decline.","Proposed acquisition of Seagen (oncology ADC) expected to close late 2023 or early 2024; integration planning underway."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-014759","json":"https://secwatch.observer/filing/0001628280-23-014759.json","markdown":"https://secwatch.observer/filing/0001628280-23-014759.md","text":"https://secwatch.observer/filing/0001628280-23-014759.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/78003/000162828023014759/0001628280-23-014759-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/78003/000162828023014759/pfe-20230502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T04:13:52.145185+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3fc5e760e44f5c55a9f38a937e1c414851599bb7","claim":"PFIZER INC reported first quarter of 2023 results: revenue $18,282 million, net income $5,543 million, EPS $0.97 per diluted share. Guidance reaffirmed.","evidence_excerpt":"except as shall be expressly set forth by specific reference in such filing. --- EX-99 (EX-99) --- Pfizer Reports First-Quarter 2023 Results ▪ First-Quarter 2023 Revenues of $18.3 Billion – Expected Decline in Comirnaty (1) Revenue Drove 26% Operational Decrease in First-Quarter 2023 Revenues – First-Quarter 2023 Revenues from Comirnaty (1) and Paxlovid of $7.1","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/78003/000162828023014759/0001628280-23-014759-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2023"},{"label":"Revenue","value":"$18,282 million"},{"label":"Net income","value":"$5,543 million"},{"label":"EPS","value":"$0.97 per diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}